Local websites
Businesses
Other websites
General contact

Head Office
Novartis International AG
CH-4002 Basel
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)

More information

Investors

Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel
Switzerland

+41 61 324 79 44

More information

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

More information

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

 

Latest news

21-May-2013
New data reinforces strength of Novartis once-daily COPD portfolio in improving lung function, shortness of breath and reducing rate of exacerbations

21-May-2013
Largest-ever global survey of 1,273 women in 12 countries reveals women with advanced breast cancer feel left out of the breast cancer movement

17-May-2013
Novartis drug Afinitor® significantly extended time without disease progression in women with HER2 positive advanced breast cancer

Investor Insights logo

Investor Insights is a newsletter in which you will find:

  • Interesting feedback we have recently received from investors
  • Investor FAQs
  • Updates on specific Novartis initiatives and happenings

Stay up-to-date

View Novartis images on Flickr

Subscribe to the Novartis YouTube channel

English newsfeed

German newsfeed

French newsfeed

Top links
Top downloads
Stock chart

Stock performance

Annual report cover

Annual Report and Form 20-F 2012 >